PMC11544843 PMC / NIH NAD+ biosynthesis, aging, and longevity control: sirtuins overview
Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome
How Dihexa fits within RWAs cognitive wellness framework RWA often considers Dihexa as part of a broader neuropeptide protocol sometimes used in sequence with Cerebrolysin (for clinical research base), Semax or Selank (for acute BDNF support and anxiety management), and NAD+ IV therapy (for cellular energy and DNA repair)
Long-term studies on oral and liposomal glutathione are fewer in number but have not identified significant adverse effects at typical supplemental doses
The GLP-1 category is approaching another important inflection point, driven mainly by the launch of oral therapies and the expansion of Medicare access in the U.S., says Terence Flynn, who leads coverage of U.S